Source comparison
What Researchers Measure vs What TB-500 Delivers
Most TB-500 studies measure surrogate markers. VEGF expression, actin filament density, integrin clustering. Rather than migration itself. That's because true migration assays (transwell chambers, wound scratch tests) require controlled environments that don't
This comparison does not assign a generated winner or score.
- Most TB-500 studies measure surrogate markers. VEGF expression, actin filament density, integrin clustering. Rather than migration itself. That's because true migration assays (transwell chambers, wound scratch tests) require controlled environments that don't translate cleanly to in vivo models. When researchers do measure migration directly, they're often quantifying keratinocyte movement across a wound gap or endothelial sprouting into a collagen matrix. Endpoints that depend on TB-500 plus baseline wound healing capacity.
- A 2017 study in PLOS One used a transwell migration assay to test TB-500's effect on human dermal fibroblasts. Migration increased by 40% compared to control after 24 hours of TB-500 exposure. But only when the assay included a chemoattractant gradient (FBS in the lower chamber). Without the gradient, TB-500 alone produced no directional bias. The peptide accelerates migration when the cellular machinery is already primed to move; it doesn't initiate movement from a resting state.
- This distinction matters for timeline expectations. If a researcher administers TB-500 to healthy, uninjured tissue and measures migration markers, the response will be minimal because there's no injury signal activating the repair cascade. TB-500 works synergistically with endogenous wound healing. It doesn't replace it. Studies that miss this context often report disappointing timelines because they're measuring the wrong phase of the process.